Virtu Financial LLC Takes $50,000 Position in Acelyrin, Inc. (NASDAQ:SLRN)

Virtu Financial LLC acquired a new position in Acelyrin, Inc. (NASDAQ:SLRN) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 10,080 shares of the company’s stock, valued at approximately $50,000.

A number of other hedge funds also recently added to or reduced their stakes in SLRN. Acadian Asset Management LLC purchased a new stake in shares of Acelyrin in the 2nd quarter worth approximately $590,000. Almitas Capital LLC bought a new position in Acelyrin in the second quarter worth approximately $1,659,000. Point72 Asset Management L.P. lifted its holdings in Acelyrin by 566.7% during the third quarter. Point72 Asset Management L.P. now owns 250,300 shares of the company’s stock worth $1,234,000 after buying an additional 212,758 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Acelyrin by 81.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 609,678 shares of the company’s stock valued at $3,006,000 after acquiring an additional 273,604 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new stake in Acelyrin during the 2nd quarter valued at $693,000. 87.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on SLRN shares. HC Wainwright restated a “neutral” rating and set a $8.00 price objective on shares of Acelyrin in a research note on Wednesday, December 11th. Wells Fargo & Company decreased their price target on shares of Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th.

Acelyrin Price Performance

Acelyrin stock opened at $3.15 on Friday. Acelyrin, Inc. has a 1-year low of $3.11 and a 1-year high of $8.89. The business has a fifty day moving average price of $5.01 and a 200-day moving average price of $4.97. The stock has a market capitalization of $316.03 million, a price-to-earnings ratio of -1.28 and a beta of 1.61.

Acelyrin Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.